Outlook Therapeutics (OTLK) Asset Writedowns and Impairment (2018 - 2020)

Outlook Therapeutics (OTLK) has 3 years of Asset Writedowns and Impairment data on file, last reported at -$27624.0 in Q3 2020.

• Asset Writedowns and Impairment for Q3 2020 came in at -$27624.0, down 100.33% year-over-year; the trailing twelve-month figure through Sep 2020 was $8.8 million (down 21.85% YoY), and the FY2020 annual result was $500000.0, down 95.56% from the prior year.
• Asset Writedowns and Impairment fell to -$27624.0 in Q3 2020 per OTLK's latest filing, from $104296.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $8.3 million in Q3 2019 and troughed at -$27624.0 in Q3 2020.
• A 3-year average of $1.7 million and a median of $423328.0 in 2020 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 104.8% in 2020 and fell as far as 100.33% in 2020.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $2.3 million in 2018, then jumped by 253.62% to $8.3 million in 2019, then tumbled by 100.33% to -$27624.0 in 2020.
• Business Quant data shows OTLK's Asset Writedowns and Impairment at -$27624.0 in Q3 2020, $104296.0 in Q2 2020, and $423328.0 in Q1 2020.